AbbVie has signed a deal with C2N Diagnostics to develop and commercialise the latter’s portfolio of anti-tau antibodies for the treatment of Alzheimer’s disease and other neurological disorders.
Tau stabilises proteins responsible for the structure and transport in neuronal cells, but its abnormal accumulation is a characteristic of many neurodegenerative conditions.
Explaining AbbVie’s interest in the deal, Jim Sullivan, chief of pharmaceutical discovery at the firm, said C2N’s portfolio of anti-tau antibodies represents “one of the most promising approaches to delaying progression of devastating neurodegenerative disease”.
Financial terms of the deal were kept under wraps.
